Overview

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, NB medication results in superior outcomes compared with placebo.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Yale University

Treatments:

Bupropion
Bupropion hydrochloride, naltrexone hydrochoride drug combination
Naltrexone